These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32106257)

  • 1. Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease.
    Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Matono T; Kato J; Tokunaga S; Sugihara T; Hiramatsu A; Hyogo H; Tobita H; Sato S; Kawanaka M; Hara Y; Hino K; Chayama K; Murawaki Y; Isomoto H
    PLoS One; 2020; 15(2):e0219412. PubMed ID: 32106257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.
    Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Kato J; Tokunaga S; Sugihara TA; Hara Y; Hino K; Murawaki Y
    PLoS One; 2016; 11(5):e0154676. PubMed ID: 27135827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.
    Salvoza NC; Klinzing DC; Gopez-Cervantes J; Baclig MO
    PLoS One; 2016; 11(4):e0153497. PubMed ID: 27077736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
    Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
    JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.
    Yamada H; Ohashi K; Suzuki K; Munetsuna E; Ando Y; Yamazaki M; Ishikawa H; Ichino N; Teradaira R; Hashimoto S
    Clin Chim Acta; 2015 Jun; 446():267-71. PubMed ID: 25958847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Nonalcoholic Fatty Liver Disease through a Panel of Plasma Biomarkers and MicroRNAs in Female West Virginia Population.
    Pillai SS; Lakhani HV; Zehra M; Wang J; Dilip A; Puri N; O'Hanlon K; Sodhi K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD).
    Jampoka K; Muangpaisarn P; Khongnomnan K; Treeprasertsuk S; Tangkijvanich P; Payungporn S
    Microrna; 2018; 7(3):215-222. PubMed ID: 29848284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
    Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
    Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients.
    Ye D; Zhang T; Lou G; Xu W; Dong F; Chen G; Liu Y
    Life Sci; 2018 Sep; 208():201-207. PubMed ID: 30030064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population.
    Ando Y; Yamazaki M; Yamada H; Munetsuna E; Fujii R; Mizuno G; Ichino N; Osakabe K; Sugimoto K; Ishikawa H; Ohashi K; Teradaira R; Ohta Y; Hamajima N; Hashimoto S; Suzuki K
    Sci Rep; 2019 Dec; 9(1):18856. PubMed ID: 31827150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver.
    Yamada H; Suzuki K; Ichino N; Ando Y; Sawada A; Osakabe K; Sugimoto K; Ohashi K; Teradaira R; Inoue T; Hamajima N; Hashimoto S
    Clin Chim Acta; 2013 Sep; 424():99-103. PubMed ID: 23727030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased MiR-155 Level in the Peripheral Blood of Non-Alcoholic Fatty Liver Disease Patients may Serve as a Biomarker and may Influence LXR Activity.
    Wang L; Zhang N; Wang Z; Ai DM; Cao ZY; Pan HP
    Cell Physiol Biochem; 2016; 39(6):2239-2248. PubMed ID: 27832630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
    Tan Y; Ge G; Pan T; Wen D; Gan J
    PLoS One; 2014; 9(8):e105192. PubMed ID: 25141008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased Serum miR-1296 may Serve as an Early Biomarker for the Diagnosis of Non-Alcoholic Fatty Liver Disease.
    Yu F; Wang X; Zhao H; Hao Y; Wang W
    Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
    Hochreuter MY; Dall M; Treebak JT; Barrès R
    Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation.
    Erhartova D; Cahova M; Dankova H; Heczkova M; Mikova I; Sticova E; Spicak J; Seda O; Trunecka P
    PLoS One; 2019; 14(11):e0224820. PubMed ID: 31703079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological marker of non‑alcoholic fatty liver disease.
    Jiang H; Qian Y; Shen Z; Liu Y; He Y; Gao R; Shen M; Chen S; Fu Q; Yang T
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33955511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease.
    Lei L; Zhou C; Yang X; Li L
    Clin Exp Pharmacol Physiol; 2018 Aug; 45(8):819-831. PubMed ID: 29569260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
    Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
    Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GRHL2 induces liver fibrosis and intestinal mucosal barrier dysfunction in non-alcoholic fatty liver disease via microRNA-200 and the MAPK pathway.
    Wang Y; Zeng Z; Guan L; Ao R
    J Cell Mol Med; 2020 Jun; 24(11):6107-6119. PubMed ID: 32324317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.